Evaluation of Antioxidant and Anti-Parkinson Activity of Portulaca oleracea Seed Methanolic Extract

Main Article Content

Santosh Kumar Vaidya
Dharmesh K. Golwala
Darpini S. Patel
Satyajit Sahoo


Aim: Evaluation of Antioxidant and Anti-Parkinson activity of Portulaca oleracea seed methanolic extract.

Place: C. U. Shah College of Pharmacy and Research, Wadhwan, Surendranagar, Gujarat, India.

Methodology: Collect plant materials were extracted with methanol. Extract was subjected to qualitative and quantitative investigation and antioxidant properties of extract was determine by Nitric oxide free radical scavenging activity and Reducing power by FeCl3 method.

Anti-Parkinson activity evaluated by two behavioral models namely, haloperidol induced catalepsy, and orofacial dyskinesia both models various behavioral activity/ parameter (catalepsy, vacuous chewing movement and tongue protrusion) were evaluated.

Results: Preliminary qualitative phytochemical screening was to reveal presence of polyphenols, flavanoids, glycoside, alkaloids, carbohydrates and reducing sugar etc. Based preliminary qualitative phytochemical screening; quantitative estimation of methanolic extract showed significant amount of polyphenols. In-vitro antioxidants was performed by two method reducing power by FeCl3 and nitric oxide free radical scavenging, the methanolic extract shows significant antioxidant properties, based on polyphenols and antioxidant properties extracts was used for the Anti-Parkinson activity Haloperidol induced catalepsy in mice Treatment with Portulaca oleracea seed showed a significant (P<0.01) reduction in the duration of cataleptic behavior dose dependently when compared to haloperidol treated group. Haloperidol induced orofacial dyskinesia in rat recovery of orofacial dyskinesia as evidenced by decrease in the frequency of vacuous chewing movement and tongue significant (P<0.05) decrease in the frequency of vacuous chewing & tongue protrusion while Portulaca oleracea seed (200 mg/kg) was found to be insignificant in this respect.

Conclusion: After Portulaca oleracea seed (MLPO) treatment, the significant alterations produced in Parkinson’s affected rodents in respect to lipid peroxidation and antioxidant concentration significantly contributing its antioxidant potential. This antiperoxide action observed in Portulaca oleracea seed (MLPO) treated animals might be due to the suppression of the production of reactive oxygen species. This compound may be found to scavenge free radicals, including hydroxyl anions and reduce the level of lipid peroxidation in MLPO animals. Inhibition of oxidative stress may be one of the possible mechanisms for the anti-Parkinson effects of Portulaca oleracea seed (MLPO).

Portulaca oleracea seed, alkaloids, antioxidant, Orofacial dyskinesia, vacuous chewing movements and methanolic extract.

Article Details

How to Cite
Vaidya, S. K., Golwala, D. K., Patel, D. S., & Sahoo, S. (2020). Evaluation of Antioxidant and Anti-Parkinson Activity of Portulaca oleracea Seed Methanolic Extract. European Journal of Medicinal Plants, 31(2), 10-17. https://doi.org/10.9734/ejmp/2020/v31i230211
Original Research Article


Lev N, Melamed E, Offen D. Apoptosis and Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(2):245-50.

Singha S, Dikshit M. Apoptotic neuronal death in Parkinson’ involvement of nitric oxide. Brain Res Rev. 2007;54(2):233- 250.

Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother. 2004;58(1): 39-46.

Ciccone CD. Free-radical toxicity and antioxidant medications in Parkinson’s disease. Phys and Ther. 1998;78(3):313-319.

Kabra MP, Bhandari SS, Sharma A, Gupta RB. Evaluation of Anti-Parkinson's activity of gentisic acid in different animal models. Journal of Acute Disease. 2014;3(2):141-144.

Chatterjee A, Chandra S. The treatise on Indian medicinal plants. Publ Informa Directorate. 1956;1:243-44.

Kole PL, Jadav H, Thakurdesi P. The cosmetic potential of herbal extract. Nat Prod Radiat. 2005;4(4):351-352.

Uddin MK, Juraimi AS, Anwar F, Hossainm A, Alam MA. Effect of salinity on proximate mineral composition of purslane (Portulaca oleracea L.). Australian Journal of Crop Science. 2012;6(12):1732-1736.

Liu LX, Howe P, Zhou YF. Fatty acid and B carotene in Australian Pursalne. J Chromatogr. 2000;893(1):207-13.

Chen HB, Zhou W, Zhao W, Zhou Q, Uan G. Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PAR and FAS mRNA expression in high-fat diet induced mice. Molecular Biology Reports. 2012;39(8): 7981-7988.

Mohamed Dkhil A, Moneim E, Al Nasr I. Nuronal activities of Portulaca oleracea in adult rats. J of Medicinal Plant Res. 2012;6(16):3162-68.

Yue ME, Jiang TF, Shi YP. Simultaneous determination of noradrenaline and dopamine in Portulaca oleracea L. by capillary zone electrophoresis. Journal of Separation Science. 2005;28(4):360–364.

Nadkarni KM, Nadkarni AK. Indian Materia Medica. Popular Prakashan, Mumbai; 1999.

Chan K, Islam MW, Kamil M. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. Journal of Ethnopharmacology. 2000;73(3):445-451.

Liu l, Peter H, Ue-Fang Z, Zhi-Qiang X, Charles H, Ren Z. Fatty acids and b-carotene in Australian Purslane (Portulaca oleracea) varieties. Journal of Chromatography. 2000;893:207-213.

Rangari VD. Pharmacognosy & Phytochemistry. 8th Ed. Nashik: Career Publication; 2008.

Harbone JR. Phytochemical methods: A guide to modern techniques of plant analysis. Science Paperbacks; 1984.

Golwala DK, Patel LD. Pharmacognostical Studies of Bauhinia variegate Linn. Stem International J. of Pharmaceutical Res. 2012;4(4):1-4.

Vaidya SK, Bothara SB. Total Polyphenolic content and In-vitro antioxidant potential of extracts of creeping herb Ipomoea reniformis (Roxb.) Choisy. American J. of Phytomed and Clin. Therapeutics. 2014;2(12):1462-1469.

Bhalodia NR, Pankaj B, Nariya R, Acharya N, Shukla VJ. In vitro antioxidant activity of hydro alcoholic extract from the fruit pulp of Cassia fistula Linn. Ayurveda. 2013; 34(2):209-214.

Boora F, Chirisa E, Mukanganyama S. Evaluation of nitrite radical scavenging properties of selected Zimbabwean plant extracts and their phytoconstituents. J of Food Processing. 2014;1-7.

Vogel HG, Vogel WH, Scholkens BA, Sandow J, Muller G. Drug discovery and evaluation, pharmacological assays. 2nd Ed. Heidelburg: Springer; 2002.

Dawson TM. New animal models for Parkinson’s disease. Cell. 2000;101:115-118.

Rodriquez DM, Abdala P, Barroso-Chinea P, Obeso J, Gonzdez-Hernandez T. Motor behavioral changes after intracerebroventricular injection of 6-hydroxy dopamine in the rat: An animal model of Parkinson’s disease. Behav. Brain Res. 2001;122(1):79-92.

Chandra S, Chen X, Rizo J, Jahn R, Sudho TC. A broken α helix in folded α synuclein. J Biol. Chem. 2003;278(17): 15313-15318.

Jicha GA, Salmone JD. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: Possible relations to Parkinsonian symptoms. J Neurosci. 1991;11(12):3822- 3829.

Paille V, Brachet P, Damier P. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson’s disease. Neuroreport. 2004;15(3):561-564.

Marin C, Saldana M, Roca-Ferrer J, Bonastre M, Aguilar E, Mullol J. Striatal and nigral COX-2 expression after chronic typical and atypical neuroleptic administration in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 2007;31: 678-682.

Lohr JB. Oxygen free radicals and neuropsychiatric illness. Arch Gen Psychiat. 1991;48(12):1097-1106.

Arniaz SL, Coronel MF, Boveris A. Nitric oxide, superoxide, and hydrogen peroxide production in brain mitochondria after haloperidol treatment. Nitric Oxide. Schizophrenia Bulletin. 2004;30(4):235-243.

Nehru B, Verma R, Khanna P, Sharma SK. Behavioral alterations in model of Parkinson’s diseases: Attenuation by cotreatment of. Brain Res. 2008;1201:122-127

Jenner P. Oxidative mechanisms in Nigral cell death in Parkinson’s disease. Mov Disord. 1998;13(1):24-34.